US Pharma MarketingThe post Curis opens 11 sites for emavusertib combo in TakeAim CLL trial appeared first on Clinical Trials Arena.
Curis opens 11 sites for emavusertib combo in TakeAim CLL trial
Curis has opened enrolment at 11 clinical sites for its Phase II TakeAim CLL trial, assessing the oral small molecule inhibitor emavusertib along with zanubrutinib for patients with CLL. Curis plans to dose the initial five patients by the end of July 2026, with data anticipated in December 2026. The open-label trial will examine the dual inhibition strategy targeting NF-kB. Credit: Gorodenkoff/Shutterstock.com. Curis has opened enrolment at 11 clinical sites for its Phase II TakeAim CLL trial to assess the oral small molecule inhibitor emavusertib, along with zanubrutinib, for patients with chronic lymphocytic leukaemia (CLL). The company also reaffirmed that…
Curis has opened enrolment at 11 clinical sites for its Phase II TakeAim CLL trial, assessing the oral small molecule inhibitor emavusertib along with zanubrutinib for patients with CLL.
Source: Clinical Trials Arena